Table 1.
Peptide | Position | Overlap | |
---|---|---|---|
TAYFSLDTR | 66-74 | None | |
VTEPLDR | 216-222 | None | |
NTGVISVVTTGLDR | 332-335 | EP-22 | KNMFTINRNTGVISVVTTGLDRESFPTYTL |
GQVPENEANVVITTLK | 382-397 | EP-13, partially EP-23 |
IFNPTTYKGQVPENEANVVITTLKVTDADAPN TVTDTNDNPPIFNPTTYKGQVPENEANVVITTLKVTDADAPN |
DTANWLEINPDTGA | 528-541 | None | |
ISTRAELDR | 542-550 | None | |
TIFFCER | 559-565 | None | |
MALEVGDYK | 656-664 | None | |
EPLLPPEDDTR | 739-749 | EP-17 | LRRRAVVKEPLLPPEDDTRDNVYYYDE |
GLDARPEVTR | 775-784 | Partially EP-14 | FDLSQLHRGLDARPEVTRNDVAPTLM |
NDVAPTLMSVPR | 785-796 | EP-14 | DARPEVTRNDVAPTLMSVPRYLPRPANP |
PANPDEIGNFIDENLK | 801-816 | Partially EP-15 | SVPRYLPRPANPDEIGNFIDENLKAADTDPTAPPYD |
NOTE. The left column indicates the peptides identified in patient tissue, the second column shows its position in the full E-cadherin protein, and the right columns indicate overlap with in vitro neutrophil elastase digestion of E-cadherin. Highlighted text indicates peptides identified in patient samples, and underlined text indicates peptides before trypsin treatment. Boxed text indicates E-cadherin peptides generated by NE cleavage.